MYOVANT SCIENCES

 MYOVのチャート


 MYOVの企業情報

symbol MYOV
会社名 Myovant Sciences Ltd (MYOVANT SCIENCES)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 Myovant Sciences Ltd is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix which is an oral once-daily small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids endometriosis-associated pain and advanced prostate cancer. The Company is developing MVT-602 an oligopeptide kisspeptin agonist for the treatment of female infertility.  マイオバント・サイエンシズはバミュ―ダ諸島籍のバイオ医薬品企業。臨床段階で、主に女性特有の疾患と前立腺がんに対する治療薬の開発・商業化に従事する。同社パイプライン「Relugolix」は子宮筋腫、子宮内膜症、前立腺がんを治療する経口薬。また、「RVT-602」は女性の不妊症治療に利用される。本社はハミルトン。  Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.
本社所在地 Suite 1 3rd Floor 11-12 St. James's Square London SW1Y 4LB GBR
代表者氏名 Myrtle Stephens Potter
代表者役職名 Chairman of the Board
電話番号 +44 1824-8101
設立年月日 42401
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 86人
url www.myovant.com
nasdaq_url
adr_tso
EBITDA (百万ドル) -240.29900
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 1730.65800
売上高 (百万ドル) 0.00000
企業価値(EV) (百万ドル) 1646.33100
当期純利益 (百万ドル) -245.74100
決算概要 BRIEF: For the nine months ended 31 December 2018 Myovant Sciences Ltd revenues was not reported. Net loss increased from $95M to $198.5M. Higher net loss reflects Research and development - Balancing increase from $74M to $158.3M (expense) General and administrative - Balancing increase of 87% to $21.2M (expense) Interest expense increase from $904K to $4.8M (expense).

 MYOVのテクニカル分析


 MYOVのニュース

   Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020  2020/11/02 13:30:00 GlobeNewswire
BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for…
   Global Cancer Care Market Latest Innovative Solutions to Boost Global Growth, Overview, Driver, Restraints, Deployments and Key Players 2027||Sanofi, Ipsen Pharma, AbbVie Inc., Myovant Sciences Ltd., Bayer AG, AstraZeneca, Tolmar Pharmaceuticals  2020/10/26 06:52:20 OpenPR
According to the latest report published by Data Bridge Market Research, the Cancer Care Market is anticipated to grow at a steady pace over the forecast period 2020 – 2027. The report sheds light on the various trends and restraining
   Correction: Financial Markets-Stocks story  2020/10/01 13:49:00 ABC News
In a story September 29, 2020, which included information about Myovant Sciences' potential prostate cancer drug, The Associated Press erroneously reported that the drug failed to meet multiple goals in a study
   Mid-Afternoon Market Update: Gold Rises 1%; Myovant Sciences Shares Plunge  2020/09/29 15:06:00 Benzinga
Toward the end of trading Tuesday, the Dow traded down 0.23% to 27520.96 while the NASDAQ fell 0.01% to 11,116.40. The S&P also fell, dropping 0.22% to …
   After a strong run, what's next for investors in Myovant Sciences?  2020/09/14 08:33:53 Stockopedia
If you've ever found yourself feeling increasingly drawn to a stock that's constantly rising in price, you are not alone…
   After a strong run, what's next for investors in Myovant Sciences?  2020/09/14 08:33:53 Stockopedia
If you've ever found yourself feeling increasingly drawn to a stock that's constantly rising in price, you are not alone…
   Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals  2020/08/05 12:30:00 GlobeNewswire
USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma to further support planned commercialization of relugolix…
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Myovant's stock gains on promising endometriosis drug trial  2020/06/23 13:02:07 MarketWatch
Shares of Myovant Sciences Ltd. undefined gained 7% in premarket trading on Tuesday after the drugmaker said a late-stage clinical trial for its experimental…
   Myovant Eyes Relugolix Combo Approval for Uterine Fibroids  2020/06/02 15:44:00 Zacks Investment Research
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 MYOVANT SCIENCES MYOV )

 twitter  (公式ツイッターやCEOツイッターなど)